Patel Amar, Fong Lawrence
Oncology (Williston Park). 2018 Mar 15;32(3):112-20.
Immunotherapies have emerged as a revolutionary modality for cancer treatment, and a variety of immune-based approaches are currently being investigated in the field of prostate cancer. Despite the 2010 approval of sipuleucel-T, subsequent progress in prostate cancer immunotherapy development has been limited by disappointing results with novel vaccination approaches and by prostate cancer's general resistance to immune checkpoint blockade. Nevertheless, there remains strong preclinical and clinical evidence to suggest that prostate cancer is a susceptible target for immune therapies. Innovative strategies for vaccine development, adoptive cell transfer, alleviation of immunosuppression in the tumor microenvironment, and combinatorial approaches using existing drugs and novel immune agents hold great promise for improving the treatment of prostate cancer. The first article in this two-part series will provide an overview of both past and present therapeutic vaccination strategies for the promotion of antitumor immunity against prostate cancer. Later, in Part 2, we will discuss novel areas of clinical development and identify the trends that may define the future of prostate cancer immunotherapy.
免疫疗法已成为癌症治疗的一种革命性方式，目前前列腺癌领域正在研究多种基于免疫的方法。尽管2010年西妥昔单抗获得批准，但随后前列腺癌免疫疗法的发展受到新疫苗接种方法令人失望的结果以及前列腺癌对免疫检查点阻断普遍耐药的限制。然而，仍有强有力的临床前和临床证据表明前列腺癌是免疫疗法的易感靶点。疫苗开发、过继性细胞转移、减轻肿瘤微环境中的免疫抑制以及使用现有药物和新型免疫制剂的联合方法等创新策略，对于改善前列腺癌治疗具有巨大潜力。这个两部分系列文章的第一篇将概述过去和目前促进针对前列腺癌的抗肿瘤免疫的治疗性疫苗接种策略。随后，在第二部分中，我们将讨论临床开发的新领域，并确定可能定义前列腺癌免疫疗法未来的趋势。
